Main > > >PSORIASIS. *

---

Derma.>Plaque Psoriasis. TREAT.: AdalimuMAb BioSimilar. (D)
EU Approval Date : 2017. 11.13.
USA Approval Date: 2017. 08.29.
(*) Company : Boehringer Ingelheim
TradeMark: Cyltezo
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: AdalimuMAb BioSimilar.
EU Approval Date : 2017. 03.23.
EU Launch Date : 2018. 10.16.
USA Approval Date: 2016. 09.23.
USA Launch Date : 2023. 01.31.
(*) Company : Amgen
TradeMark: Amgevita or Amjevita
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: AdalimuMAb BioSimilar.
EU Approval Date: 2017. 08.24.
EU Launch Date: 2018. 10.17.
(*) Company : Biogen
Developed By: Samsung Bioepis
TradeMark : IMRALDI
UpDate: 2018. 10.30.




Derma.>Plaque Psoriasis. TREAT.: AdalimuMAb Brand.
EU Approval Date : 2003. 08.09.
USA Approval Date: 2002. 12.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.12.




Derma.>Plaque Psoriasis. TREAT.: Apremilast 30 mg Tablets.
Oral PDE-4 Inhibitor.
CA Approval Date : 2020. 02.12.
EU Approval Date : 2015. 01.15.
JP Approval Date : 2016. 12.20.
USA Approval Date: 2014. 09.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.10.




Derma.>Plaque Psoriasis. TREAT.: Betamethasone DiPropionate Spray 0.05%.
USA Launch Date: 2016. 06.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: Betamethasone DiPropionate+Calcipotriene Foam (Spray) 0.064%/0.005%.
EU Approval Date: 2016. 03.18.
USA Approval Date: 2015. 10.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.12.




Derma.>Plaque Psoriasis. TREAT.: Betamethasone DiPropionate+Calcipotriene Topical Suspension 0.064%/0.005%.
Patent>USA Expiration: 2021. 10.
USA Approval Date: 2012. 10.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.12.




Derma.>Plaque Psoriasis. TREAT.: BrodaluMAb Injection
for Subcutaneous Use.
IL-17 Receptor AntAgonist.
EU Approval Date: 2017. 07.20.
JP Approval Date: 2016. 07.
USA Approval Date: 2017. 02.16.
USA Launch Date: 2017. 07.27.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.:
CertolizuMAb Pegol.
CA Approval Date: 2019. 03.25.
USA Approval Date: 2018. 05.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.26.




Derma.>Plaque Psoriasis. TREAT.: Clobetasol Propionate Cream 0.025%.
USA Approval Date: 2017. 12.01.
USA Launch Date: 2018. 05.01.
(*) Company; Patent & TradeMark
Available on Request.
UpDate: 2018. 05.02.




Derma.>Plaque Psoriasis. TREAT.: Desoximetasone Topical
Spray. Brand.
USA Approval Date: 2013. 04.11.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: Desoximetasone Topical
Spray. Generic.
USA Approval Date: 2017. 01.24.
USA Launch Date: 2018. 12.10,
(*) Company: Perrigo
UpDate: 2018. 12.11.




Derma.>Plaque Psoriasis. TREAT.: DiMethyl Fumarate. Brand.
EU Approval Date: 2017. 06.27.
(*) Company & TradeMark Available on
Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: Etanercept. BioSimilar.
USA Approval Date: 2016. 08.30.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: Etanercept. Brand.
Adults (>18) USA Approval Date: 2004. 04.30.
Children (4-17) USA Approval Date: 2016. 11.04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: GuselkuMAb. Brand
Fully Human Anti-IL-23 MAb.
AU Approval Date : ?
BR Approval Date : ?
CA Approval Date : 2017. 11.15.
EU Approval Date : 2017. 11.23.
JP Approval Date : ?
KR Approval Date : 2018. 04.26.
USA Approval Date: 2017. 07.13.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 04.28.




Derma.>Plaque Psoriasis. TREAT.: Home Light Therapy Device. (N)
USA Approval Date: 2017. 07.13.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2018. 01.08.




Derma.>Psoriasis. Plaque Psoriasis. TREAT.:
Home Light Therapy Device. (U)
USA Launch Date: 2018. 12.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.06.




Derma.>Plaque Psoriasis. TREAT.: InflixiMAb BioSimilar.
Approved in EU; KR & USA.
(*) Companies & TradeMarks Available on
Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.:
InflixiMAb-axxq BioSimilar.
USA Approval Date: 2019. 12.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 04.11.




Derma.>Plaque Psoriasis. TREAT.: InflixiMAb Brand.
Mechanism: TNF Alpha Inhibitor.
USA Approval Date: 2006. 09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: InflixiMAb dyyb BioSimilar.
Approved Also in AU; BR; EU.
USA Approval Date: 2016. 04.05.
USA Launch Date: 2016. 10.17.
(*) Company & TradeMarks Available on
Request.
UpDate: 2017. 12.15.




Derma.>Plaque Psoriasis. TREAT.: InflixiMAb qbtx BioSimilar.
Chimeric Human-Murine MAb against tumor necrosis factor
USA Approval Date: 2017. 12.13.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.14.




Derma.>Plaque Psoriasis. TREAT.: IxekizuMAb Injection
80 mg/mL.
IL-17A Humanized IgG4 MAb.
USA Approval Date: 2016. 03.22.
USA Availability Date: 2016. 05.02.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2017. 12.05.




Derma.>Psoriasis. Plaque Psoriasis. TREAT.: RisankizuMAb Injection.
Mechanism: IL-23 Inhibition.
CA Approval Date : 2019. 04.18.
EU Approval Date : 2019. 04.30.
JP Approval Date : 2019. 03.19.
USA Approval Date: 2019. 04.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.11.




Derma.>Plaque Psoriasis. TREAT.: SecukinuMAb.
Target: IL-17A.
AU; CA; CH; EU & JP Also Approved.
USA Approval Date: 2015. 01.21.
(*) Company; Patent; TradeMark & Web-
Site Available on Request
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.:
TildrakizuMAb. Brand.
Adults who are candidates for systemic therapy or phototherapy. TildrakizuMAb Selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines. TildrakizuMAb is administered at a dose of 100 mg by subcutaneous injection every 12 weeks, after the completion of initial doses at weeks 0 and 4.
USA Approval Date: 2018. 03.21.
USA Launch Date: 2018. 10.23.
(*) Company; Patent,TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.24.




Derma.>Plaque Psoriasis. TREAT.: UstekinuMAb.
Mechanism: IL-12 & IL-23 Inhibition.
USA Adolescents Approval Date: 2017. 10.16.
USA Adults Approval Date : 2009. 09.25.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.08.




Derma.>Plaque Psoriasis. TREAT.: Vitamin D Analog.
Calcitriol Topical 3 Microgr/Gr.
CH Approval Date: ?
EU Approval Date: ?
USA Approval Date: 2009. 02.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.13.




Treat. (Plaque Psoriasis): Betamethasone Dipropionate Spray 0.05%. Generic.
USA Tentative Approval: 2019. 04.04.
(*) Company: Perrigo.
UpDate: 2019. 04.05.





>PSORIASIS. *'s products
This section has no products